Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

Easton J. D., Lopes R. D., Bahit M. C., Wojdyla D. M., Granger C. B., Wallentin L., ...Daha Fazla

LANCET NEUROLOGY, cilt.11, sa.6, ss.503-511, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 6
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1016/s1474-4422(12)70092-3
  • Dergi Adı: LANCET NEUROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.503-511
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Background In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA.